**UDC 57.084:612.12:615.33**

**THE INFLUENCE OF THE PEGYLATED ANTIBIOTIC ENROFLOXACIN**

**ON BLOOD PROTEIN CONTENT AND LIVER STRUCTURE OF RATS**

**O.Zelenina1, V.Vlizlo2, M.Skrypka1, D.Ostapiv3, V.Naida1, L.Afanasyeva1, T.Kemal1**

*1Odessa State Agrarian University*

*2Lviv National University of Veterinary Medicine and Biotechnology named after Stepan Gzhytsky,*

*3Institute of Animal Biology of NAAS*

**References**

1 Atef, M., El-Banna, H., Elzorba, H., & Soliman, A. M. (2020). Pharmacokinetics and tissue residue of enrofloxacin in healthy, *Eimeria*-infected broiler chickens and those pre-treated with amprolium and toltrazuril. *International journal of veterinary science and medicine*, *8*(1), 31–38. <https://doi.org/10.1080/23144599.2020.1765720>

2 Avgoustakis K. (2004). Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. *Current drug delivery*, *1*(4), 321–333. <https://doi.org/10.2174/1567201043334605>.

3 Barman D.A., Phukan, D.N., Kalita, T.C. Dutta, Mahato, G., P Borah, Rajkhowa, S., & Baishya, B.C. (2023). Efficacy of enrofloxacin over cefalexin in the therapeutic management of canine dermatitis. *The Pharma Innovation Journal*. *12*(1), 2385-2388. <https://www.thepharmajournal.com/archives/?year=2023&vol=12&issue=1&ArticleId=18314>

4 Barry, R.L. (2007). PEG as a tool to gain insight into membrane fusion. Eur. Biophys. J., 36(4–5), 315–326. <https://doi.org/10.1007/s00249-006-0097-z>.

5 Bird, S., Etminan, M., Brophy, J., Hartzema, A., & Delaney, J. (2013). Risk of acute kidney injury associated with the use of fluoroquinolones. *CMAJ: Canadian Medical Association journal*, *185*(10), E475–E482. <https://doi.org/10.1503/cmaj.121730>

6 Camus, M. S., Krimer, P. M., Leroy, B. E., & Almy, F. S. (2010). Evaluation of the positive predictive value of serum protein electrophoresis beta-gamma bridging for hepatic disease in three domestic animal species. *Veterinary pathology*, *47*(6), 1064–1070. <https://doi.org/10.1177/0300985810375946>

7 Caruthers, S., Wickline, S., & Lanza, G. (2007). Nanotechnological applications in medicine. *Current opinion in biotechnology*, *18*(1), 26–30. <https://doi.org/10.1016/j.copbio.2007.01.006>

8 Cattaneo, L., Lopreiato, V., Piccioli-Cappelli, F., Trevisi, E., & Minuti, A. (2021). Plasma albumin-to-globulin ratio before dry-off as a possible index of inflammatory status and performance in the subsequent lactation in dairy cows. *Journal of dairy science*, *104*(7), 8228–8242. <https://doi.org/10.3168/jds.2020-19944>

9 Chekh, B.,  Ferens, M., Ostapiv, D., Samaryk, V., Varvarenko, S., Vlizlo V. (2017). Characteristics of novel polymer based on pseudo-polyamino acids GluLa-DPG-PEG600:binding of albumin, biocompatibility,biodistribution and potential crossing theblood-brain barrier in rats. *The Ukrainian Biochemical Journal*, *89*(4), 13-21. <http://nbuv.gov.ua/UJRN/BioChem_2017_89_4_4>

10 Chen, M., Yang, Y., Ying, Y., Huang, J., Sun, M., Hong, M., Wang, H., Xie, S., & Chen, D. (2023). ABC Transporters and CYP3A4 Mediate Drug Interactions between Enrofloxacin and Salinomycin Leading to Increased Risk of Drug Residues and Resistance. *Antibiotics (Basel, Switzerland)*, *12*(2), 403. <https://doi.org/10.3390/antibiotics12020403>

11 Clegg, J., Souza, C., & Brame B. (2023). Tolerability of Otic Solutions Containing Different Enrofloxacin Concentrations in Dogs with Healthy Ears. *J Am Anim Hosp Assoc*, *59*(5), 214–218. <https://doi.org/10.5326/JAAHA-MS-7363>.

12 Dron, I. A., Vynnytska, S. I., Oleksa, V. V., Khom’iak, S. V., & Ostapiv, D. D. (2018). Syntez i doslidzhennia antybakterialnoi aktyvnosti pehilovanykh enrofloksatsyniv. *Visnyk Natsionalnoho universytetu Lvivska politekhnika.* *886,* 47-51. [http://nbuv.gov.ua/UJRN/VNULPX\_2018\_886\_9](http://www.irbis-nbuv.gov.ua/cgi-bin/irbis_nbuv/cgiirbis_64.exe?I21DBN=LINK&P21DBN=UJRN&Z21ID=&S21REF=10&S21CNR=20&S21STN=1&S21FMT=ASP_meta&C21COM=S&2_S21P03=FILA=&2_S21STR=VNULPX_2018_886_9)

13 Fuchs, K., Rinder, M., Dietrich, R., Banspach, L., Ammer, H., & Korbel, R. (2022). Penetration of Enrofloxacin in Aqueous Humour of Avian Eyes. *Veterinary sciences*, *10*(1), 5. <https://doi.org/10.3390/vetsci10010005>

14 Grabowski, L., Gaffke, L., Pierzynowska, K., Cyske, Z., Choszcz, M., Węgrzyn, G., & Węgrzyn, A. (2022). Enrofloxacin-The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?. *International journal of molecular sciences*, *23*(7), 3648. <https://doi.org/10.3390/ijms23073648>

15 Hewitt, M., Cronin, M. T., Enoch, S. J., Madden, J. C., Roberts, D. W., & Dearden, J. C. (2009). In silico prediction of aqueous solubility: the solubility challenge. *Journal of chemical information and modeling*, *49*(11), 2572–2587. https://doi.org/10.1021/ci900286s

16 Jain, S., Gautam, V., & Naseem, S. (2011). Acute-phase proteins: As diagnostic tool. *Journal of pharmacy & bioallied sciences*, *3*(1), 118–127. https://doi.org/10.4103/0975-7406.76489

17 Katarey, D., & Verma, S. (2016). Drug-induced liver injury. *Clinical medicine (London, England)*, *16*( 6), 104–109. <https://doi.org/10.7861/clinmedicine.16-6-s104>

18 Kozak, M., Stasiuk, A., Vlizlo, V., Ostapiv, D., Bodnar, Y., Kuz’mina, N., Figurka, N., Nosova, N., Ostapiv, R., Kotsumbas, I., Varvarenko, S., & Samaryk, V. Polyphosphate Ester-Type Transporters Improve Antimicrobial Properties of Oxytetracycline. Antibiotics 2023, 12 (3), 616. https://doi.org/10.3390/antibiotics12030616.

19 Kozak, M., Zelenina, O., Ostapiv, D., Skrypka, M., Samaryk, V., &Vlizlo,V. (2023). Blood creatinine content and rat kidney structure after intramuscular injection of pegylated antibiotic enrofloxacin. *Biol. Stud.,17*(3):47–56. <https://doi.org/10.30970/sbi.1703.720>.

20 Kumar, S., Singh, D., Kumari, P., Malik, R. S., Poonam, Parang, K., & Tiwari, R. K. (2020). PEGylation and Cell-Penetrating Peptides: Glimpse into the Past and Prospects in the Future. *Current topics in medicinal chemistry*, *20*(5), 337–348. <https://doi.org/10.2174/1568026620666200128142603>

21 Luan, Y., Chen, K., Zhao, J., & Cheng, L. (2022). Comparative Study on Synergistic Toxicity of Enrofloxacin Combined with Three Antibiotics on Proliferation of THLE-2 Cell. *Antibiotics. 11*(3), 394. <https://doi.org/10.3390/antibiotics11030394>.

22 Ma, B., Mei, X., Lei, C., Li, C., Gao, Y., Kong, L., Zhai, X., & Wang, H. (2020). Enrofloxacin Shifts Intestinal Microbiota and Metabolic Profiling and Hinders Recovery from Salmonella enterica subsp. *enterica* Serovar Typhimurium Infection in Neonatal Chickens. *mSphere*, *5*(5), e00725-20. <https://doi.org/10.1128/mSphere.00725-20>

23 Mozar, F. S., & Chowdhury, E. H. (2018). Impact of PEGylated Nanoparticles on Tumor Targeted Drug Delivery. *Current pharmaceutical design*, *24*(28), 3283–3296. <https://doi.org/10.2174/1381612824666180730161721>

24 Otsuka, H., Nagasaki, Y., & Kataoka, K. (2003). PEGylated nanoparticles for biological and pharmaceutical applications. *Advanced drug delivery reviews*, *55*(3), 403–419. <https://doi.org/10.1016/s0169-409x(02)00226-0>.

25  Piras, C., Soggiu, A., Greco, V., Martino, P. A., Del Chierico, F., Putignani, L., Urbani, A., Nally, J. E., Bonizzi, L., & Roncada, P. (2015). Mechanisms of antibiotic resistance to enrofloxacin in uropathogenic Escherichia coli in dog. *Journal of proteomics*, *127*(Pt B), 365–376. <https://doi.org/10.1016/j.jprot.2015.05.040>

26 Popp, M., Gerhards, H., & Wollanke, B. (2013). Enrofloxacin concentrations in the vitreous of horses with equine recurrent uveitis (ERU) after repeated intravenous administration. *Pferdeheilkunde*. *29*, 574-580. https://doi.org/[10.21836/PEM20130501](http://dx.doi.org/10.21836/PEM20130501)

28 PrakashR.G., Adilaxmamma, G., Srividya, T., &Madhava R. (2023). In-vitro synergistic antibacterial activity of Punganur cow urine on enrofloxacin*. Int J Vet Sci Anim Husbandry, 8*(2), 102-106. <https://doi.org/10.22271/veterinary.2023.v8.i2b.501>.

27 Sanchez Armengol, E., Unterweger, A., & Laffleur, F. (2022). PEGylated drug delivery systems in the pharmaceutical field: past, present and future perspective. *Drug development and industrial pharmacy*, *48*(4), 129–139. <https://doi.org/10.1080/03639045.2022.2101062>

28 Simonov, M. & Vlizlo, V. (2015). Some blood markers of the functional state of liverin dairy cows with clinical ketosis. *Bulgarian Journal of Veterinary Medicine*, *18* (1), 74–82. https://doi.org/[10.15547/bjvm.814](http://dx.doi.org/10.15547/bjvm.814)

29 Smith, A., Pennefather, P., Kaye, S. &Hart C. (2001). Fluoroquinolones. *Drugs,* 61, 747–761. <https://doi.org/10.2165/00003495-200161060-00004>

30 Srinivasu, M., Singh, S., &Ahmad, A. (2022). Pathak Abhishek. Effect of enrofloxacin and ciprofloxacin on oxidative stress in rats*. Journal Of Veterinary Pharmacology And Toxicology. 21*(1), 80-82. ISSN: 0972-8872.

<https://www.indianjournals.com/ijor.aspx?target=ijor:jvpat&volume=21&issue=1&article=018>

31 Szatmári, V., van Dongen, A.M., Restrepo, T.M., den Toom, M.L. & Jongejan, N. (2023). Successful Clindamycin Therapy of an Infected Subcutaneous Permanent Pacing Lead in a Dog after a Failed Course with Potentiated Amoxicillin and Enrofloxacin. *Veterinary sciences*, *10*(2), 93. <https://doi.org/10.3390/vetsci10020093>.

32 Tarushi, A., Raptopoulou, C., Psycharis, V., Terzis, A., Psomas, G., & Kessissoglou, D. (2010). Zinc(II) complexes of the second-generation quinolone antibacterial drug enrofloxacin: Structure and DNA or albumin interaction. *Bioorganic & medicinal chemistry*, *18*(7), 2678–2685. <https://doi.org/10.1016/j.bmc.2010.02.021>

33 Temmerman, R., Ghanbari, M., Antonissen, G., Schatzmayr, G., Duchateau, L., Haesebrouck, F., Garmyn, A., & Devreese, M. (2022). Dose-dependent impact of enrofloxacin on broiler chicken gut resistome is mitigated by synbiotic application. *Frontiers in microbiology*, *13*, 869538. https://doi.org/10.3389/fmicb.2022.869538

34 Tothova, C., Nagy, O.& Kovac, G. (2016). Serum proteins and their diagnostic utility in veterinary medicine: a review. *Veterinarni Medicina*, *61*, 475-496. <https://doi.org/10.17221/19/2016-VETMED>

35 Trouchon, T. & Lefebvre, S. (2016) A Review of Enrofloxacin for Veterinary Use*. Journal of Veterinary Medicin*e, 6, 40-58. <https://doi.org/10.4236/ojvm.2016.62006>.

36 Van Schyndel, S. J., Dubuc, J., Pascottini, O. B., Carrier, J., Kelton, D. F., Duffield, T. F., & LeBlanc, S. J. (2021). The effect of pegbovigrastim on early-lactation disease, production, and reproduction in dairy cows. *Journal of dairy science*, *104*(9), 10100–10110. <https://doi.org/10.3168/jds.2021-20266>.

37 Wang, J., Li, S., Han, Y., Guan, J., Chung, S., Wang, C., & Li, D. (2018). Poly(Ethylene Glycol)-Polylactide Micelles for Cancer Therapy. *Frontiers in pharmacology*, *9*, 202. <https://doi.org/10.3389/fphar.2018.00202>.

38 Weese, J., Giguère, S., Guardabassi, L., Morley, P., Papich, M., Ricciuto, D., & Sykes, J. (2015). ACVIM consensus statement on therapeutic antimicrobial use in animals and antimicrobial resistance. *Journal of veterinary internal medicine*, *29*(2), 487–498. <https://doi.org/10.1111/jvim.12562>

39 Westropp, J. L., Sykes, J. E., Irom, S., Daniels, J. B., Smith, A., Keil, D., Settje, T., Wang, Y. & Chew, D.J. (2012). Evaluation of the Efficacy and Safety of High Dose Short Duration Enrofloxacin Treatment Regimen for Uncomplicated Urinary Tract Infections in Dogs. Journal of Veterinary Internal Medicine. *26*(3). 506-512. <https://doi.org/10.1111/j.1939-1676.2012.00914.x>.

40 Wright, D., Brown, G., Peterson, M., & Rotschafer, J. (2000). Application of fluoroquinolone pharmacodynamics. *The Journal of antimicrobial chemotherapy*, *46*(5), 669–683. <https://doi.org/10.1093/jac/46.5.669>

41 Yang, S.-Y., Zhao, F.-K., Pang, H., Chen, L.-Z., Shi, R.-B. & Fang, B.-H. (2022). Pharmaceutical Cocrystals and Salts of Enrofloxacin: Structure and Properties, *Journal of Molecular Structure*, 133335, ISSN 0022-2860, <https://doi.org/10.1016/j.molstruc.2022.133335>.

42 Zdvizhkov, Yu. & Bura. M. (2014). Osoblyvosti zastosuvannia polimernykh nosiiv na osnovi polietylenhlikoliu dlia dostavky likiv v orhan-mishen. *Visnyk Lvivskoho universytetu.* *64*, 3-20. <http://nbuv.gov.ua/UJRN/VLNU_biol_2014_64_3>.

43 Zelenina, O., Vlizlo, V., Kozak, M., Ostapiv, D., Samaryk, V., Dron, I., Stetsko, T., Skrypka, M., Tomchuk, V., Danchuk, O. & Levchenko, A. Antimicrobial activity of the PEGylated antibiotic enrofloxacin and its functional and structural effect on the liver in rats. Journal of Applied Pharmaceutical Science. 2022. 12(06), 068-075. [https://doi.org/10.7324/JAPS.2022.120607. ISSN 2231-3354](https://doi.org/10.7324/JAPS.2022.120607.%20ISSN%202231-3354)